Wang Jiabing, Yun Di, Yao Jiali, Fu Weitao, Huang Fangyan, Chen Liping, Wei Tao, Yu Cuijuan, Xu Haineng, Zhou Xiaoou, Huang Yanqing, Wu Jianzhang, Qiu Peihong, Li Wulan
Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical Universtiy, Wenzhou, Zhejiang 325035, China; Wenzhou Biomedical Innovation Center, Wenzhou University and Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical Universtiy, Wenzhou, Zhejiang 325035, China.
Eur J Med Chem. 2018 Jan 20;144:493-503. doi: 10.1016/j.ejmech.2017.12.043. Epub 2017 Dec 18.
Molecular hybridization is considered as an effective tactic to develop drugs for the treatment of cancer. A series of novel hybrid compounds of isatin and Michael acceptor were designed and synthesized on the basis of association principle. These hybrid compounds were tested for cytotoxic potential against human cancer cell lines namely, BGC-823, SGC-7901 and NCI-H460 by MTT assay. Most compounds showed good anti-growth activities in all tested human cancer cells. SAR and QSAR analysis may provide vital information for the future development of novel anti-cancer inhibitors. Notably, compound 6a showed potent growth inhibition on BGC-823, SGC-7901 and NCI-H460 with the IC values of 3.6 ± 0.6, 5.7 ± 1.2, 3.2 ± 0.7 μM, respectively. Besides, colony formation assays, wound healing assays and flow cytometry analysis indicated 6a exhibited a potent anti-growth and anti-migration ability in a concentration-dependence manner through arrested cells in the G2/M phase of cell cycle. Moreover, 6a significantly repressed tumor growth in a NCI-H460 xenograft mouse model. Overall, our findings suggested isatin analogues inspired Michael acceptor may provide promising lead compounds for the development of cancer chemotherapeutics.
分子杂交被认为是开发抗癌药物的一种有效策略。基于关联原理设计并合成了一系列新型的异吲哚酮与迈克尔受体的杂化化合物。通过MTT法检测了这些杂化化合物对人癌细胞系BGC-823、SGC-7901和NCI-H460的细胞毒性潜力。大多数化合物在所有测试的人癌细胞中均表现出良好的抗生长活性。构效关系(SAR)和定量构效关系(QSAR)分析可为新型抗癌抑制剂的未来开发提供重要信息。值得注意的是,化合物6a对BGC-823、SGC-7901和NCI-H460表现出强效的生长抑制作用,其IC值分别为3.6±0.6、5.7±1.2、3.2±0.7μM。此外,集落形成试验、伤口愈合试验和流式细胞术分析表明,6a通过使细胞停滞在细胞周期的G2/M期,以浓度依赖性方式表现出强效的抗生长和抗迁移能力。此外,6a在NCI-H460异种移植小鼠模型中显著抑制肿瘤生长。总体而言,我们的研究结果表明,受迈克尔受体启发的异吲哚酮类似物可能为癌症化疗药物的开发提供有前景的先导化合物。